Emerging Disease News and Research

RSS
Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

Study: 13 zoonoses responsible for 2.4B cases of human illness per year

Study: 13 zoonoses responsible for 2.4B cases of human illness per year

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity voluntarily stops saridegib Phase 2 trial for chondrosarcoma

Infinity voluntarily stops saridegib Phase 2 trial for chondrosarcoma

ICDs may increase risk of complications in patients with infective endocarditis

ICDs may increase risk of complications in patients with infective endocarditis

New data from Infinity saridegib and gemcitabine Phase 1b/2 combination trial on pancreatic cancer

New data from Infinity saridegib and gemcitabine Phase 1b/2 combination trial on pancreatic cancer

ViroPharma to acquire Meritage

ViroPharma to acquire Meritage

Infinity third quarter total revenue increases marginally to $23.3 million

Infinity third quarter total revenue increases marginally to $23.3 million

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

New research aims to control transmission of infectious diseases

New research aims to control transmission of infectious diseases

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Infinity provides guidance on anticipated pipeline and business goals for 2011

Infinity provides guidance on anticipated pipeline and business goals for 2011

Infinity named to NASDAQ Global Select Market

Infinity named to NASDAQ Global Select Market

Infinity extends global strategic alliance with Mundipharma for development, commercialization of IPI-926

Infinity extends global strategic alliance with Mundipharma for development, commercialization of IPI-926

Researchers synthesize iron compounds that inhibit growth of Mycobacterium tuberculosis

Researchers synthesize iron compounds that inhibit growth of Mycobacterium tuberculosis

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program